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PEGylated β Subunit Intra-Molecular Cross-linked Bovine 
Hemoglobin Based Oxygen Carrier Blood Substitute
Methods of Characterization
• SELC to determine molecular size distribution using running buffer was 50mM
MgCl2, with flow rate of 0.3mL/min, sample Load of 100uL on a Superose 12 column
• MALDI-ToF MS to determine molecular weight determination using a matrix 3,5-
Dimethoxy-4-hydroxycinnamic acid (Sinapinic acid), solvent of a 50:50:0.1 ratio of
acetonitrile, diH2O2, trifluoroacetic acid (TFA), sample to matrix/solvent ratio was
50:50 and samples were loaded onto a 96 spot stainless steel plate
• UV-Vis Absorbance Spectroscopy to determine oxidation states and protein
concentration
• SDS-PAGE to determine the purity and impurity using a resolving and stacking of
15.0% and 5.0% acrylamide, potential and duration was at 75-110 Volts for 90
minutes, and Coomasie Blue stain
Methods of Studying Oxidative Stress under Hydrogen 
Peroxide Challenge
Initial Kinetics using different molar concentrations of Hb:H2O2 1:0, 600, 750, 900 
and 1050
Long Term Kinetics using constant molar concentration of Hb:H2O2 1:14,500
• Optical Absorption Spectroscopy using UV-Vis to determine the kinetic reactions  
and the formation of Ferrylhemoglobin (Fe4+) and Methemoglobin (Fe3+)
• HbFe2+O2 + H2O2 → HbFe
4+ = O + H2O + O2 [Eq. 5]
• HbFe4+ = O + H2O2 → HbFe
3+ + O∙-2 + H2O [Eq. 6]
• EPR Spectroscopy studies to shows formation of Methemoglobin and Superoxide
• ΔE=hν=gµBBo [Eq. 7]
• Iron Release Assay of long term H2O2 challenge to determine the concentration and 
percentage of complete iron dissociation from porphyrin using ortho-phenanthroline
and Fe2+ produces an orange-reddish color
Blood substitutes that are stable and functional been sought after for many years and 
recently HBOCs have been at the forefront.  Although the intentions of a blood 
substitute is not completely replace the need for whole blood, it is often 
misunderstood due to the word substitute.  A more semantically realistic term would 
be ancillary blood substitute.  Understanding the purpose of HBOCs we can begin to 
realize the advantages and limitations of application.  From there new methods can be 
develop to either enhance the advantages or tackle the limitation issues.  HBOC 
should not be a permanent replacement of whole blood, but ideally it should be 
temporarily provide similar oxygen carrying capability, maintain oncotic pressure, and 
minimized oxidative stress.  The two main focus of this thesis was the preparation and 
characterization of bovine Hb β-β subunit cross-linking and PEGylation.  Both 
modifications shown significant stability under oxidative stress relative to BSFHb, 
although BPEGXLHb did show a marginally less stable than BXLHb under UV-Vis 
spectrometry, but EPR and Fe4+ release did show that BPEGXLHb had a higher 
attenuation of hydrogen peroxide and produce less concentrations of Fe4+.  This slight 
decrease in stability of BPEGXLHb under UV-Vis is acceptable, due to the gain in 
vascular retention of the increase MW from the conjugation of the 10 PEG.  The data 
provided evidence that bovine Hb β-β subunit cross-linking prior to PEGylation 
provided a notable degree of conformational stability, but did not provide much 
protection for the Fe during the oxidative stress challenge.  The evidence shows that 
PEGylated β-β subunit cross-linked Hb does provide a conformational stability, can 
attenuate oxidative stress and reduced potential toxicity from ROS.  BPEGXLHb also 
provides improved vascular retention and increase oncotic pressure due to the 
increased MW from the PEG chains.  Further modification to increase antioxidant 
capabilities coupled with the wide range of different methods of PEGylation, 
BPEGXLHb has the potential to be a functional and stable HBOC.
We hope to address the challenges of availability, immunologic response, the short yet 
stable half-life, increased oxygen affinity, attenuate oxidative stress, and enhance 
vasoactive properties.  The issue of stability was made apparent from past research 
that observed Hb α subunits are less stable than that of the β subunits and tends to 
dissociate from the tetramer structure.  Resolution to this issue was intramolecular 
cross-linking α subunits which increase the stability of the HBOC.  Using well 
established methods of cross-linking human Hb α subunits and altering it for cross-
linking bovine Hb β subunits was done by changing the initial conformational structure 
of deoxyHb to OxyHb.  The aim of this research was to determine if cross-linking the 
more stable β subunits will have greater stability for the overall Hb tetramer through 
cooperative stability.  
Unmodified cell free Hemoglobin (CFH) or stroma free hemoglobin (SFHb) was well as 
intramolecular cross-linked subunits alone are too small to be and effective HBOC.  
The molecular size of said HBOC are small enough to easily diffuse from the vascular 
system into the interstitial tissue.  Excessive amounts of HBOC in interstitial tissue can 
lead to unwanted side effects.  SFHb also triggers auto scavenging effects of vascular 
enzymes that specifically targets either the heme or globin protein of the Hb.  The aim 
is to increase the MW without interfering with the oxygen carrying capability of the 
HBOC.  Increasing MW can be achieved by the conjugation of polyethylene glycol (PEG) 
of desired MW to the Hb.  Past research has shown that PEG conjugation (PEGylation) 
does increase vascular retention as well as mitigate auto scavenging, immune 
response and increase oncotic pressure.  Stability of the final HBOC can be done by 
subjecting it to similar conditions that warrant the use of an HBOC namely conditions 
involving trauma.  During traumatic conditions in which the damaged areas of the 
body releases peroxides as a means of degrading the damaged cells, more oxygen in 
these areas.  With the need of oxygen in damaged areas, HBOC must be stable and 
functional under conditions with elevated peroxide concentrations.  We aim to 
simulate a traumatic environment by subjecting the HBOC with various concentrations 
and durations of peroxides and compare each one to BSFHb as a standard to 
determine the stability of BPEGXLHb.
Hemoglobin based oxygen carriers (HBOC) have the potential characteristics to fill the
clinical needs that are not met by normal blood transfusions. The raw material sources
for HBOC come from an unlimited supply of outdated human donor or bovine blood,
which can eliminate the issue of shortages and blood type complications. This
characteristic applicable in treatment of individuals during accidents in remote locations
or even used in battlefields where military hospitals may be hundreds of miles away. By
combining know methods of hemoglobin (Hb) modifications, I was able to create stable
and novel new HBOC. Methods of intramolecular cross-linking of bovine Hb (BXLHb) β-β
subunits then further modifications on surface residues using 5kDa molecular weight
(MW) polyethylene glycol (PEG) chains was used to produce a bovine polyethylene glycol
cross-linked hemoglobin (BPEGXLHb). This new HBOC was characterized and studied
using oxidative stress under hydrogen peroxide (H2O2) challenge. Evidence shows that
the combination of methods did provide the final product with structural stability as well
as attenuate oxidative stress and limit the formation of superoxides.
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• A = εbc [Eq. 1]
• [Oxyhemoglobin] = (119*A577 – 39*A630 –89*A560)/DF [Eq. 2]
• [Methemoglobin] = (28* A577 + 307* A630 –55* A560)/DF [Eq. 3]
• [Total Hemoglobin] = [Eq. 2] + [Eq.3] in micromole (M) [Eq. 4]
• Percentage [Methemoglobin] = ([Eq.2]/ [Eq. 4])*100%
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UV-Vis Fe Release
OD mM
BSFHb 0.3965 0.1089
BXLHb 0.1924 0.0632
BPEGXLHb 0.1452 0.0526
Fe Released by H2O2
mM % Fe out
BSFHb 0.109 11.843
BXLHb 0.063 6.871
BPEGXLHb 0.052 5.721
